价格

TCR-1

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS
EP 3700924 A4申请人: UNIV CALIFORNIA优先权: 2017
CN
EP
US
WO
15 件公开
CONJUGATED ANTIBODY OR BISPECIFIC TCELL ENGAGER WHICH SELECTIVELY BINDS EITHER TCR BETA CONSTANT REGION 1 (TRBC1) OR TRBC2
EP 4736887 A2申请人: AUTOLUS LTD优先权: 2014
CN
EP
US
WO
11 件公开
MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES
- EP 4265642 B1
  申请人: GAMMADELTA THERAPEUTICS LTD优先权: 2020
  CN
  EP
  WO
  9 件公开
- US 12312408 B2
  申请人: GAMMADELTA THERAPEUTICS LTD优先权: 2021
  US
  3 件公开
- US 20260152558 A1
  申请人: GAMMADELTA THERAPEUTICS LTD优先权: 2024
  US
  WO
  2 件公开
TCR AND PEPTIDES
EP 4585681 A3申请人: OSPEDALE SAN RAFFAELE SRL优先权: 2017
CN
EP
US
WO
8 件公开
TCR-T CELL FOR KILLING TUMORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
US 2024293454 A1申请人: GUANGZHOU FINELMMUNE BIOTECHNOLOGY CO LTD优先权: 2020
CN
US
8 件公开
NOVEL ANTI-TCR DELTA VARIABLE 1 ANTIBODIES
EP 4013504 A1申请人: GAMMADELTA THERAPEUTICS LTD优先权: 2019
CN
EP
US
WO
7 件公开
GENE EDITING T CELL AND USE THEREOF
EP 3686275 A4申请人: EDIGENE INC优先权: 2017
CN
EP
US
WO
5 件公开
PRAME TCR RECEPTORS AND USES THEREOF
EP 4061827 A1申请人: BIONTECH SE优先权: 2019
CN
EP
US
WO
5 件公开
Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
US 10781243 B2申请人: MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT优先权: 2015
CN
EP
US
5 件公开
ANTI-TCR DELTA VARIABLE 1 ANTIBODIES
EP 4294527 A1申请人: GAMMADELTA THERAPEUTICS LTD优先权: 2021
EP
US
WO
5 件公开

药物

TCR-1

专利

MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES